IXC — Invex Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$5.64m
- -AU$0.17m
- AU$1.70m
- 78
- 65
- 42
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.05 | ||
| Price to Tang. Book | 1.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.91 | ||
| EV to EBITDA | -1.49 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.12% | ||
| Return on Equity | 2.14% | ||
| Operating Margin | 7.92% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.17 | 0.16 | 0.26 | 1.26 | 1.7 | n/a | n/a | 566.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP) including traumatic brain injury (TBI), stroke and hydrocephalus. In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Presendin is the Company’s filed (and granted) trademark name for reformulated Exenatide. The Company is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.
Directors
- Jason Loveridge NEC
- Alexandra Sinclair CSO
- Thomas Duthy EDR
- Narelle Warren SEC
- Megan Baldwin NID
- David Mcauliffe NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 8th, 2019
- Public Since
- July 5th, 2019
- No. of Shareholders
- 1,141
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 75,153,848
- Address
- Level 2, 38 Rowland St, Subiaco, PERTH, 6008
- Web
- https://invextherapeutics.com/
- Phone
- Contact
- Thomas Duthy
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for IXC
Similar to IXC
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Invex Therapeutics share price?
As of Today at 21:22 UTC, shares in Invex Therapeutics are trading at AU$0.08. This share price information is delayed by 15 minutes.
How has the Invex Therapeutics share price performed this year?
Shares in Invex Therapeutics last closed at AU$0.08 and the price had moved by -6.25% over the past 365 days. In terms of relative price strength the Invex Therapeutics share price has underperformed the ASX All Ordinaries Index by -9.65% over the past year.
What are the analyst and broker recommendations for Invex Therapeutics?
There is no consensus recommendation for this security.
Find out moreWhat is the Invex Therapeutics dividend yield?
Invex Therapeutics does not currently pay a dividend.
Does Invex Therapeutics pay a dividend?
Invex Therapeutics does not currently pay a dividend.
When does Invex Therapeutics next pay dividends?
Invex Therapeutics does not currently pay a dividend.
How do I buy Invex Therapeutics shares?
To buy shares in Invex Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Invex Therapeutics?
As of the previous close price of AU$0.08, shares in Invex Therapeutics had a market capitalisation of AU$5.64m.
Where are Invex Therapeutics shares listed?
Here are the trading details for Invex Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IXC
What kind of share is Invex Therapeutics?
Based on an overall assessment of its quality, value and momentum Invex Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Invex Therapeutics share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Invex Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Invex Therapeutics. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -14.27%.
As of the last closing price of AU$0.08, shares in Invex Therapeutics were trading -1.77% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Invex Therapeutics PE Ratio?
The Invex Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Invex Therapeutics?
Invex Therapeutics' management team is headed by:
- Jason Loveridge - NEC
- Alexandra Sinclair - CSO
- Thomas Duthy - EDR
- Narelle Warren - SEC
- Megan Baldwin - NID
- David Mcauliffe - NID